Dr Reddy's Launches Generic Anti-Bacterial Drug in US
By Rediff Money Desk, New Delhi May 03, 2024 16:11
Dr Reddy's Laboratories has launched a generic Doxycycline Capsules (40 mg) in the US market, a therapeutic equivalent of Oracea capsules (40 mg).
New Delhi, May 3 (PTI) Dr Reddy's Laboratories on Friday said it has launched a generic medication, used to treat a wide variety of bacterial infections, in the US market.
The company has launched Doxycycline Capsules (40 mg) in the US market, the Hyderabad-based drug maker said in a statement.
The company's product is a therapeutic generic equivalent of Oracea capsules (40 mg) approved by the US Food and Drug Administration (USFDA).
Shares of the company on Friday ended 0.71 per cent up at Rs 6,332.85 apiece on the BSE.
The company has launched Doxycycline Capsules (40 mg) in the US market, the Hyderabad-based drug maker said in a statement.
The company's product is a therapeutic generic equivalent of Oracea capsules (40 mg) approved by the US Food and Drug Administration (USFDA).
Shares of the company on Friday ended 0.71 per cent up at Rs 6,332.85 apiece on the BSE.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 9.17 ( -6.43)
- 158804255
- G V Films
- 0.92 ( -2.13)
- 92620172
- Srestha Finvest
- 0.93 (+ 4.49)
- 40021818
- GTL Infrastructure
- 2.21 ( -4.74)
- 33334323
- Spicejet Ltd.
- 57.56 ( -8.33)
- 31426149
MORE NEWS
Augustinus Bader Skincare & Haircare Launches...
Tira brings Augustinus Bader's luxury skincare and haircare to India, offering...
Muthoot Finance Gold Loans Now Available on...
Muthoot Finance announces that its flagship gold loans can now be availed using Google...
NCERT Books Now Available on Amazon India
NCERT textbooks for students from Kindergarten to Class 12 and UPSC aspirants are now...